Market Cap 27.99M
Revenue (ttm) 500,000.00
Net Income (ttm) -39.83M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -7,966.00%
Debt to Equity Ratio 0.00
Volume 1,668,800
Avg Vol 167,682
Day's Range N/A - N/A
Shares Out 15.21M
Stochastic %K 21%
Beta 1.37
Analysts Strong Sell
Price Target $7.44

Latest News on VYNE

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold

Apr 25, 2025, 11:55 AM EDT - 19 hours ago

FDA Puts VYNE Therapeutics Early-Stage Psoriasis Study On Hold


VYNE Therapeutics Provides Update on VYN202 Program

Apr 25, 2025, 8:00 AM EDT - 23 hours ago

VYNE Therapeutics Provides Update on VYN202 Program


VYNE Therapeutics to Participate in March Investor Conferences

Feb 20, 2025, 8:00 AM EST - 2 months ago

VYNE Therapeutics to Participate in March Investor Conferences


Menlo Ventures Raises $1.35B for AI Investments

Nov 16, 2023, 4:03 PM EST - 1 year ago

Menlo Ventures Raises $1.35B for AI Investments


VYNE Therapeutics Announces Private Placement of $88 Million

Oct 30, 2023, 7:05 AM EDT - 1 year ago

VYNE Therapeutics Announces Private Placement of $88 Million


VYNE Therapeutics to Attend BIO International Convention

May 18, 2023, 8:00 AM EDT - 2 years ago

VYNE Therapeutics to Attend BIO International Convention


VYNE Therapeutics Announces Reverse Stock Split

Feb 10, 2023, 8:00 AM EST - 2 years ago

VYNE Therapeutics Announces Reverse Stock Split